Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1CNS 1Breast 1

Conditions

Glioblastoma 2Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 51Carboplatin 21Paclitaxel 20Cyclophosphamide 18Nivolumab 13Taxes 10130-nm albumin-bound paclitaxel 10olaparib 9Specimen Handling 9spartalizumab 8fludarabine 8Doxorubicin 8durvalumab 7Magnetic Resonance Spectroscopy 7Gemcitabine 7Cisplatin 7Biopsy 7veliparib 6atezolizumab 6Fulvestrant 6Albumin-Bound Paclitaxel 6liposomal doxorubicin 5eribulin 5budigalimab 5Irinotecan 5Ipilimumab 5aldesleukin 4Radiotherapy 4Oxaliplatin 4Leucovorin 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Triple Negative Breast Neoplasms × depatuxizumab mafodotin × Clear all
NCT02365662 2018-03-30

A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor

AbbVie

Phase 1 Terminated
46 enrolled
BreastCNSGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Glioblastoma, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡